Trade Repligen Corp - RGEN CFD

About Repligen Corporation

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Repligen Corporation revenues increased 83% to $670.5M. Net income increased from $59.9M to $128.3M. Revenues reflect Product revenue - Filtration products segment increase from $174.9M to $403.5M, Product revenue - Protein products segment increase of 53% to $123.7M, Europe segment increase of 83% to $254.8M, North America segment increase of 56% to $274.9M.

Equity composition

Common Stock $.01 Par, 01/11, 40M auth., 30,787,307 issd. Insiders & strategic holders own 13.21%. PO 5/91, 2M shares @ $12.50 by Lehman Bros. Public Offering 2/94, 2.9M shares @ $6 by Lehman Brothers.